Shopping Cart 0
Cart Subtotal
AED 0

Argos Therapeutics Inc (ARGS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Argos Therapeutics Inc (Argos) is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of infectious diseases and cancer. The company develops a pipeline of products based on its proprietary Arcelis technology platform. Its Arcelis-based immunotherapies use the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos also offers AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. The company use biology of dendritic cells to activate the immune response. Argos is headquartered in Durham, North Carolina, the US.

Argos Therapeutics Inc (ARGS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Argos Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Argos Therapeutics Raises USD 60 Million In Series E Financing 13

Argos Therapeutics Raises USD 16 Million In Venture Financing 16

Argos Therapeutics Raises USD 25 Million In Series D Financing 17

Partnerships 19

Argos Therapeutics Enters into Research Agreement with Personalis 19

Invetech Enters into Agreement with Argos Therapeutics 20

Licensing Agreements 21

Argos Therapeutics to Enter into Option Agreement with Pharmstandard and Actigen 21

Argos Therapeutics Enters into Licensing Agreement with Lummy HK 22

Argos Enters Into Licensing Agreement With Medinet 23

Pharmstandard Enters into Licensing Agreement with Argos Therapeutics 24

Green Cross Enters into Licensing Agreement with Argos Therapeutics 25

Equity Offering 27

Argos Therapeutics to Raise USD6.3 Million in Public Offering of Shares 27

Argos Therapeutics to Raise USD1.5 Million in Private Placement of Shares 28

Argos Therapeutics Plans to Raise Funds through Private Placement of Shares 29

Argos Therapeutics to Raise Funds through Private Placement of Shares 30

Argos Therapeutics Raises USD5.5 Million in Public Offering of Shares 31

Argos Therapeutics Raises USD50 Million in Public Offering of Shares and Warrants 32

Argos Therapeutics Plans to Raise up to USD124 Million in Public Offering of Shares 34

Argos Therapeutics Raises USD29.8 Million in Second Tranche of Private Placement of Shares and Warrants 35

Argos Therapeutics Plans to Raise up to USD36 Million in Public Offering of Shares 36

Argos Therapeutics Raises USD20 Million in First Tranche Private Placement of Shares and Warrants 37

Argos Therapeutics Completes IPO For USD49.8 Million 39

Argos Therapeutics Raises USD12 Million in Private Placement of Shares and Warrants 41

Debt Offering 42

Argos Therapeutics Raises USD6 Million in Private Placement of 9.5% Convertible Promissory Notes Due 2022 42

Argos Therapeutics Inc-Key Competitors 43

Argos Therapeutics Inc-Key Employees 44

Argos Therapeutics Inc-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Recent Developments 46

Financial Announcements 46

Apr 02, 2018: Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights 46

Nov 09, 2017: Argos Reports Third Quarter 2017 Financial Results and Operational Highlights 49

Aug 09, 2017: Argos Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights 51

Corporate Communications 53

Jul 18, 2018: Delisting of Securities of Rosetta Genomics, ConvergeOne Holdings, (Warrant Only), FC Global Realty, Concordia International, and Argos Therapeutics from The Nasdaq Stock Market 53

Sep 26, 2017: Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors 54

Other Significant Developments 55

Nov 28, 2017: Argos Provides Financial Update 55

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Argos Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Argos Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Argos Therapeutics Raises USD 60 Million In Series E Financing 13

Argos Therapeutics Raises USD 16 Million In Venture Financing 16

Argos Therapeutics Raises USD 25 Million In Series D Financing 17

Argos Therapeutics Enters into Research Agreement with Personalis 19

Invetech Enters into Agreement with Argos Therapeutics 20

Argos Therapeutics to Enter into Option Agreement with Pharmstandard and Actigen 21

Argos Therapeutics Enters into Licensing Agreement with Lummy HK 22

Argos Enters Into Licensing Agreement With Medinet 23

Pharmstandard Enters into Licensing Agreement with Argos Therapeutics 24

Green Cross Enters into Licensing Agreement with Argos Therapeutics 25

Argos Therapeutics to Raise USD6.3 Million in Public Offering of Shares 27

Argos Therapeutics to Raise USD1.5 Million in Private Placement of Shares 28

Argos Therapeutics Plans to Raise Funds through Private Placement of Shares 29

Argos Therapeutics to Raise Funds through Private Placement of Shares 30

Argos Therapeutics Raises USD5.5 Million in Public Offering of Shares 31

Argos Therapeutics Raises USD50 Million in Public Offering of Shares and Warrants 32

Argos Therapeutics Plans to Raise up to USD124 Million in Public Offering of Shares 34

Argos Therapeutics Raises USD29.8 Million in Second Tranche of Private Placement of Shares and Warrants 35

Argos Therapeutics Plans to Raise up to USD36 Million in Public Offering of Shares 36

Argos Therapeutics Raises USD20 Million in First Tranche Private Placement of Shares and Warrants 37

Argos Therapeutics Completes IPO For USD49.8 Million 39

Argos Therapeutics Raises USD12 Million in Private Placement of Shares and Warrants 41

Argos Therapeutics Raises USD6 Million in Private Placement of 9.5% Convertible Promissory Notes Due 2022 42

Argos Therapeutics Inc, Key Competitors 43

Argos Therapeutics Inc, Key Employees 44

Argos Therapeutics Inc, Subsidiaries 45

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Argos Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Argos Therapeutics Inc (Argos) is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of infectious diseases and cancer. The company develops a pipeline of products based on its proprietary Arcelis technology platform. Its Arcelis-based immunotherapies use the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos also offers AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. The company use biology of dendritic cells to activate the immune response. Argos is headquartered in Durham, North Carolina, the US.

Argos Therapeutics Inc (ARGS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Argos Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Argos Therapeutics Raises USD 60 Million In Series E Financing 13

Argos Therapeutics Raises USD 16 Million In Venture Financing 16

Argos Therapeutics Raises USD 25 Million In Series D Financing 17

Partnerships 19

Argos Therapeutics Enters into Research Agreement with Personalis 19

Invetech Enters into Agreement with Argos Therapeutics 20

Licensing Agreements 21

Argos Therapeutics to Enter into Option Agreement with Pharmstandard and Actigen 21

Argos Therapeutics Enters into Licensing Agreement with Lummy HK 22

Argos Enters Into Licensing Agreement With Medinet 23

Pharmstandard Enters into Licensing Agreement with Argos Therapeutics 24

Green Cross Enters into Licensing Agreement with Argos Therapeutics 25

Equity Offering 27

Argos Therapeutics to Raise USD6.3 Million in Public Offering of Shares 27

Argos Therapeutics to Raise USD1.5 Million in Private Placement of Shares 28

Argos Therapeutics Plans to Raise Funds through Private Placement of Shares 29

Argos Therapeutics to Raise Funds through Private Placement of Shares 30

Argos Therapeutics Raises USD5.5 Million in Public Offering of Shares 31

Argos Therapeutics Raises USD50 Million in Public Offering of Shares and Warrants 32

Argos Therapeutics Plans to Raise up to USD124 Million in Public Offering of Shares 34

Argos Therapeutics Raises USD29.8 Million in Second Tranche of Private Placement of Shares and Warrants 35

Argos Therapeutics Plans to Raise up to USD36 Million in Public Offering of Shares 36

Argos Therapeutics Raises USD20 Million in First Tranche Private Placement of Shares and Warrants 37

Argos Therapeutics Completes IPO For USD49.8 Million 39

Argos Therapeutics Raises USD12 Million in Private Placement of Shares and Warrants 41

Debt Offering 42

Argos Therapeutics Raises USD6 Million in Private Placement of 9.5% Convertible Promissory Notes Due 2022 42

Argos Therapeutics Inc-Key Competitors 43

Argos Therapeutics Inc-Key Employees 44

Argos Therapeutics Inc-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Recent Developments 46

Financial Announcements 46

Apr 02, 2018: Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights 46

Nov 09, 2017: Argos Reports Third Quarter 2017 Financial Results and Operational Highlights 49

Aug 09, 2017: Argos Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights 51

Corporate Communications 53

Jul 18, 2018: Delisting of Securities of Rosetta Genomics, ConvergeOne Holdings, (Warrant Only), FC Global Realty, Concordia International, and Argos Therapeutics from The Nasdaq Stock Market 53

Sep 26, 2017: Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors 54

Other Significant Developments 55

Nov 28, 2017: Argos Provides Financial Update 55

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Argos Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Argos Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Argos Therapeutics Raises USD 60 Million In Series E Financing 13

Argos Therapeutics Raises USD 16 Million In Venture Financing 16

Argos Therapeutics Raises USD 25 Million In Series D Financing 17

Argos Therapeutics Enters into Research Agreement with Personalis 19

Invetech Enters into Agreement with Argos Therapeutics 20

Argos Therapeutics to Enter into Option Agreement with Pharmstandard and Actigen 21

Argos Therapeutics Enters into Licensing Agreement with Lummy HK 22

Argos Enters Into Licensing Agreement With Medinet 23

Pharmstandard Enters into Licensing Agreement with Argos Therapeutics 24

Green Cross Enters into Licensing Agreement with Argos Therapeutics 25

Argos Therapeutics to Raise USD6.3 Million in Public Offering of Shares 27

Argos Therapeutics to Raise USD1.5 Million in Private Placement of Shares 28

Argos Therapeutics Plans to Raise Funds through Private Placement of Shares 29

Argos Therapeutics to Raise Funds through Private Placement of Shares 30

Argos Therapeutics Raises USD5.5 Million in Public Offering of Shares 31

Argos Therapeutics Raises USD50 Million in Public Offering of Shares and Warrants 32

Argos Therapeutics Plans to Raise up to USD124 Million in Public Offering of Shares 34

Argos Therapeutics Raises USD29.8 Million in Second Tranche of Private Placement of Shares and Warrants 35

Argos Therapeutics Plans to Raise up to USD36 Million in Public Offering of Shares 36

Argos Therapeutics Raises USD20 Million in First Tranche Private Placement of Shares and Warrants 37

Argos Therapeutics Completes IPO For USD49.8 Million 39

Argos Therapeutics Raises USD12 Million in Private Placement of Shares and Warrants 41

Argos Therapeutics Raises USD6 Million in Private Placement of 9.5% Convertible Promissory Notes Due 2022 42

Argos Therapeutics Inc, Key Competitors 43

Argos Therapeutics Inc, Key Employees 44

Argos Therapeutics Inc, Subsidiaries 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Argos Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.